Benzinga - by Benzinga Insights, Benzinga Staff Writer.
A significant insider transaction involving the exercise of company stock options was reported on March 27, by Todd C Davis, Chief Executive Officer at Ligand Pharmaceuticals (NASDAQ:LGND), as per the latest SEC filing.
What Happened: Disclosed in a Form 4 filing on Wednesday with the U.S. Securities and Exchange Commission, Davis, Chief Executive Officer at Ligand Pharmaceuticals, executed a strategic derivative sale. This involved exercising stock options for 16,015 shares of LGND, resulting in a transaction value of $252,004.
Currently, Ligand Pharmaceuticals shares are trading up 2.61%, priced at $73.13 during Thursday's morning. This values Davis's 16,015 shares at $252,004.
About Ligand Pharmaceuticals Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Ligand Pharmaceuticals's Financial Performance Decline in Revenue: Over the 3 months period, Ligand Pharmaceuticals faced challenges, resulting in a decline of approximately -44.22% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Holistic Profitability Examination:
- Gross Margin: With a high gross margin of 94.16%, the company demonstrates effective cost control and strong profitability relative to its peers.
- Earnings per Share (EPS): Ligand Pharmaceuticals's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 1.05.
Valuation Analysis:
- Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 23.52 is lower than the industry average, indicating potential undervaluation for the stock.
- Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 9.64 suggests overvaluation in the eyes of investors, considering sales performance.
- EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): Ligand Pharmaceuticals's EV/EBITDA ratio of 10.98 exceeds industry averages, indicating a premium valuation in the market
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
The Importance of Insider Transactions Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
A Deep Dive into Insider Transaction Codes When analyzing transactions, investors tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Ligand Pharmaceuticals's Insider Trades.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.